EKF Diagnostics Holdings
EKF Diagnostics Holdings, the AIM-listed global diagnostics business, has announced the launch of its new Biosen C-Line (Biosen), an advanced version of its industry leading rapid benchtop glucose and lactate analyser.
The new and updated analyser has been designed to enhance usability with the latest colour, touch screen and advanced connectivity, enabling the Biosen to seamlessly connect with hospital and laboratory IT systems, via EKF Link, to ensure patient results are quickly and securely available to clinicians.
The Biosen analyser measures glucose and lactate levels in whole blood, plasma and serum, using enzymatic sensor technology to give highly precise results, less than 3% CV. It is used by clinical professionals in both primary and secondary care settings around the world to provide glucose analysis for the detection and management of diabetes, a chronic condition which is expected to affect 1.31 billion people worldwide by 2050 according to the company.
As well as the debilitating symptoms associated with the disease, diabetes is linked to a number of serious co- morbidities including heart disease, kidney disease and obesity, therefore accurate diagnosis and careful management is critical to reduce the risk of long-term complications.
EKF says that whilst handheld Blood Glucose Monitors (BGMs) and Continuous Glucose Monitors (CGMs) remain a powerful tool for individuals looking to monitor their glycemic control, there is a growing shift for more accurate and precise glucose testing in a clinical setting using more accurate analysers like Biosen to provide deeper insights to better manage the disease.
Biosen is also used by elite sports professionals according to the company, including international football and Olympic teams, to measure lactate production during training. This provides valuable insights into the body’s metabolic responses, endurance capacity and recovery capabilities enabling coaches to tailor training strategies to individual athletes in order to achieve peak performance.
The new Biosen is also compatible with EKF Link, a middleware solution for healthcare providers to manage their POC analysers and the generated data on one centralised platform. This enables real-time remote management of data, including patient test results, quality control /calibration results, operator management and analyser configuration.
It is a fast and secure method for connecting POC devices to hospital and laboratory IT systems, enabling the safe and rapid transfer of data from the analyser to the hospital or laboratory database for subsequent processing. Additionally, unlike similar devices which typically have PC and network connectivity via the slower RS232C, all new Biosen devices have USB and encrypted ethernet interfaces, a faster and more secure connection method.
The new Biosen is also compatible with EKF Link, a middleware solution for healthcare providers to manage their POC analysers and the generated data on one centralised platform. This enables real-time remote management of data, including patient test results, quality control /calibration results, operator management and analyser configuration. It is a fast and secure method for connecting POC devices to
Gavin Jones, Chief Product Officer of EKF Diagnostics, said: “We are excited to introduce our new and updated range of Biosen C-Line glucose and lactate analysers, which address customer demand for advanced connectivity and an enhanced, user-friendly interface. Diabetes is a serious and growing global health challenge, with over 420 million people living with the disease around the world. Regular, fast and accurate monitoring is essential to effectively manage this condition and as the industry leading analyser for glucose and lactate, Biosen is well placed to help healthcare professionals deliver the best patient care.
With a number of high-profile sporting events in 2024, including the UEFA European Championship and the Paris Olympics, it is important to provide teams around the world with top class lactate analysis from the Biosen to ensure their athletes are at their peak fitness levels.”
Biosen C-Line is compliant with the new EU In Vitro Diagnostic Regulation (“IVDR”). It can run up to 120 samples per hour, delivering results in 20-45 seconds.
